Skip to main content

Advertisement

SpringerLink
Log in

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

New research findings have revealed a key role for vascular endothelial growth factor (VEGF) in the stimulation of angiogenesis in clear cell renal carcinoma (RCC) which is a highly vascularized and treatment-resistant tumor. Sorafenib (BAY 43-9006, Nexavar®) is a multi-kinase inhibitor which targets receptor tyrosine and serine/threonine kinases involved in tumor progression and tumor angiogenesis. The effect of sorafenib on tumor growth and tumor histology was assessed in both ectopic and orthotopic mouse models of RCC.

Methods

Sorafenib was administered orally to mice bearing subcutaneous (SC, ectopic) or sub-renal capsule (SRC, orthotopic) tumors of murine (Renca) or human (786-O) RCC. Treatment efficacy was determined by measurements of tumor volume and tumor growth delay. In mechanism of action studies, using the 786-O and Renca RCC tumor models, the effect of sorafenib was assessed after dosing for 3 or 5 days in the SC models and 21 days in the SRC models. Inhibition of tumor angiogenesis was assessed by measuring level of CD31 and α-smooth muscle actin (αSMA) staining by immunohistochemistry (IHC). The effect of sorafenib on MAPK signaling, cell cycle progression and cell proliferation was also assessed by IHC by measuring levels of phospho-ERK, phospho-histone H3 and Ki-67 staining, respectively. The extent of tumor apoptosis was measured by terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) assays. Finally, the effects of sorafenib on tumor hypoxia was assessed in 786-O SC model by injecting mice intravenously with pimonidazole hydrochloride 1 h before tumor collection and tumor sections were stained with a FITC-conjugated Hypoxyprobe antibody.

Results

Sorafenib produced significant tumor growth inhibition (TGI) and a reduction in tumor vasculature of both ectopic and orthotopic Renca and 786-O tumors, at a dose as low as 15 mg/kg when administered daily. Inhibition of tumor vasculature was observed as early as 3 days post-treatment, and this inhibition of angiogenesis correlated with increased level of tumor apoptosis (TUNEL-positive) and central necrosis. Consistent with these results, a significant increase in tumor hypoxia was also observed 3 days post-treatment in 786-O SC model. However, no significant effect of sorafenib on phospho-ERK, phospho-histone H3 or Ki-67 levels in either RCC tumor model was observed.

Conclusion

Our results show the ability of sorafenib to potently inhibit the growth of both ectopically- and orthotopically-implanted Renca and 786-O tumors. The observed tumor growth inhibition and tumor stasis or stabilization correlated strongly with decreased tumor angiogenesis, which was due, at least in part, to inhibition of VEGF and PDGF-mediated endothelial cell and pericyte survival. Finally, sorafenib-mediated inhibition of tumor growth and angiogenesis occurred at concentrations equivalent to those achieved in patients in the clinic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA (2003) Role of Raf in vascular protection from distinct apoptotic stimuli. Science 301:94–96

    Article  PubMed  CAS  Google Scholar 

  2. Amato RJ (2005) Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 16:7–15

    Article  PubMed  CAS  Google Scholar 

  3. An J, Fisher M, Rettig MB (2005) VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism. Oncogene 24:1563–1570

    Article  PubMed  CAS  Google Scholar 

  4. Benjamin LE, Hemo I, Keshet E (1998) A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125:1591–1598

    PubMed  CAS  Google Scholar 

  5. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159–165

    Article  PubMed  CAS  Google Scholar 

  6. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287–1295

    Article  PubMed  CAS  Google Scholar 

  7. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M (2006) BAY 43–9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98:326–334

    Article  PubMed  CAS  Google Scholar 

  8. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43–9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11:5472–5480

    Article  PubMed  CAS  Google Scholar 

  9. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev:CD001425

    Google Scholar 

  10. Ebbinghaus SW, Gordon MS (2004) Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis. Hematol Oncol Clin North Am 18:1143–1159, ix–x

    Google Scholar 

  11. Escudier B, Szczylik C, Eisin T, Stadler W, Schwartz B, Shan M, Bukowski R (2005) Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). Eur. J. Cancer Supplements 3:226

    Google Scholar 

  12. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967–974

    Article  PubMed  CAS  Google Scholar 

  13. Figlin RA (1999) Renal cell carcinoma: management of advanced disease. J Urol 161:381–6; discussion 386–387

    Google Scholar 

  14. Franco M, Man S, Chen L, Emmenegger U, Shaked Y, Cheung AM, Brown AS, Hicklin DJ, Foster FS, Kerbel RS (2006) Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 66:3639–3648

    Article  PubMed  CAS  Google Scholar 

  15. Godley PA, Taylor M (2001) Renal cell carcinoma. Curr Opin Oncol 13:199–203

    Article  PubMed  CAS  Google Scholar 

  16. Gore ME, Escudier B (2006) Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma. Oncology (Williston Park) 20:19–24

    Google Scholar 

  17. Holash J, Wiegand SJ, Yancopoulos GD (1999) New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18:5356–5362

    Article  PubMed  CAS  Google Scholar 

  18. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA (2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296:2404–2407

    Article  PubMed  CAS  Google Scholar 

  19. Hurwitz H (2004) Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 4(Suppl 2):S62–S68

    Article  PubMed  CAS  Google Scholar 

  20. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  PubMed  CAS  Google Scholar 

  21. Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9:685–693

    Article  PubMed  CAS  Google Scholar 

  22. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62

    Article  PubMed  CAS  Google Scholar 

  23. Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24–40

    Article  PubMed  CAS  Google Scholar 

  24. Josko J, Mazurek M (2004) Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med Sci Monit 10:RA89–RA98

    PubMed  CAS  Google Scholar 

  25. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R (2004) B-RAF is a therapeutic target in melanoma. Oncogene 23:6292–6298

    Article  PubMed  CAS  Google Scholar 

  26. Kim JH, Jung CW, Cho YH, Lee J, Lee SH, Kim HY, Park J, Park JO, Kim K, Kim WS, Park YS, Im YH, Kang WK, Park K (2005) Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep 13:859–864

    PubMed  CAS  Google Scholar 

  27. Mancuso A, Sternberg CN (2005) New treatments for metastatic kidney cancer. Can J Urol 12 Suppl 1: 66–70; discussion 105

    Google Scholar 

  28. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM (2000) Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 18:1928–1935

    PubMed  CAS  Google Scholar 

  29. Na X, Wu G, Ryan CK, Schoen SR, di’Santagnese PA, Messing EM (2003) Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol 170:588–592

    Article  PubMed  CAS  Google Scholar 

  30. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM, Santoro M (2006) BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 12:1623–1629

    Article  PubMed  CAS  Google Scholar 

  31. Shaheen PE, Bukowski RM (2005) Emerging drugs for renal cell carcinoma. Expert Opin Emerg Drugs 10:773–795

    Article  PubMed  CAS  Google Scholar 

  32. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP (2005) Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65:2412–2421

    Article  PubMed  CAS  Google Scholar 

  33. Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N, Murai M (2006) Renal cancer cells lacking hypoxia inducible factor (HIF)-1{alpha} expression maintain vascular endothelial growth factor expression through HIF-2{alpha}. Carcinogenesis

  34. Turner KJ, Moore JW, Jones A, Taylor CF, Cuthbert-Heavens D, Han C, Leek RD, Gatter KC, Maxwell PH, Ratcliffe PJ, Cranston D, Harris AL (2002) Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62:2957–2961

    PubMed  CAS  Google Scholar 

  35. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We thank our colleagues at Bayer for technical expertise and support.

Author information

Authors and Affiliations

  1. Department of Protein Therapeutics, Bayer Research Center, Bayer HealthCare, Pharmaceuticals, 400 Morgan Lane, West Haven, CT, 06516, USA

    Yong S. Chang, Jalila Adnane, Pamela A. Trail, Arris Henderson, Dahai Xue, Elizabeth Bortolon & Marina Ichetovkin

  2. Department of Cancer Biology, Bayer Research Center, Bayer HealthCare, Pharmaceuticals, West Haven, CT, USA

    Joan Levy, Charles Chen, Angela McNabola, Dean Wilkie, Christopher A. Carter, Ian C. A. Taylor, Mark Lynch & Scott Wilhelm

Authors
  1. Yong S. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jalila Adnane
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pamela A. Trail
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joan Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arris Henderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dahai Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Elizabeth Bortolon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marina Ichetovkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Charles Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Angela McNabola
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Dean Wilkie
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Christopher A. Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ian C. A. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Mark Lynch
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Scott Wilhelm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yong S. Chang.

Additional information

Presented in part at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, November 14–18, 2005, Philadelphia, PA, USA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chang, Y.S., Adnane, J., Trail, P.A. et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59, 561–574 (2007). https://doi.org/10.1007/s00280-006-0393-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-006-0393-4

Keywords

Search

Navigation